🎉 M&A multiples are live!
Check it out!

Fulcrum Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Fulcrum Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Fulcrum Therapeutics Overview

About Fulcrum Therapeutics

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.


Founded

2015

HQ

United States of America
Employees

45

Website

fulcrumtx.com

Financials

LTM Revenue $57.0M

LTM EBITDA n/a

EV

-$74.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Fulcrum Therapeutics Financials

Fulcrum Therapeutics has a last 12-month revenue of $57.0M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Fulcrum Therapeutics achieved revenue of $80.0M and an EBITDA of -$18.2M.

Fulcrum Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Fulcrum Therapeutics valuation multiples based on analyst estimates

Fulcrum Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $2.8M $80.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$108M -$18.2M XXX XXX XXX
EBITDA Margin -3868% -23% XXX XXX XXX
Net Profit -$110M -$97.3M XXX XXX XXX
Net Margin -3917% -122% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Fulcrum Therapeutics Stock Performance

As of April 15, 2025, Fulcrum Therapeutics's stock price is $3.

Fulcrum Therapeutics has current market cap of $158M, and EV of -$74.8M.

See Fulcrum Therapeutics trading valuation data

Fulcrum Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$74.8M $158M XXX XXX XXX XXX $-0.46

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Fulcrum Therapeutics Valuation Multiples

As of April 15, 2025, Fulcrum Therapeutics has market cap of $158M and EV of -$74.8M.

Fulcrum Therapeutics's trades at -1.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Fulcrum Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Fulcrum Therapeutics and 10K+ public comps

Fulcrum Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$74.8M XXX XXX XXX
EV/Revenue -0.9x XXX XXX XXX
EV/EBITDA 4.1x XXX XXX XXX
P/E -16.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 30.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Fulcrum Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Fulcrum Therapeutics Valuation Multiples

Fulcrum Therapeutics's NTM/LTM revenue growth is -100%

Fulcrum Therapeutics's revenue per employee for the last fiscal year averaged $1.8M, while opex per employee averaged $2.2M for the same period.

Over next 12 months, Fulcrum Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Fulcrum Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Fulcrum Therapeutics and other 10K+ public comps

Fulcrum Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 2752% XXX XXX XXX XXX
EBITDA Margin -23% XXX XXX XXX XXX
EBITDA Growth -83% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -123% XXX XXX XXX XXX
Revenue per Employee $1.8M XXX XXX XXX XXX
Opex per Employee $2.2M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 46% XXX XXX XXX XXX
R&D Expenses to Revenue 79% XXX XXX XXX XXX
Opex to Revenue 125% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Fulcrum Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Fulcrum Therapeutics M&A and Investment Activity

Fulcrum Therapeutics acquired  XXX companies to date.

Last acquisition by Fulcrum Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Fulcrum Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Fulcrum Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Fulcrum Therapeutics

When was Fulcrum Therapeutics founded? Fulcrum Therapeutics was founded in 2015.
Where is Fulcrum Therapeutics headquartered? Fulcrum Therapeutics is headquartered in United States of America.
How many employees does Fulcrum Therapeutics have? As of today, Fulcrum Therapeutics has 45 employees.
Who is the CEO of Fulcrum Therapeutics? Fulcrum Therapeutics's CEO is Mr. Alex C. Sapir.
Is Fulcrum Therapeutics publicy listed? Yes, Fulcrum Therapeutics is a public company listed on NAS.
What is the stock symbol of Fulcrum Therapeutics? Fulcrum Therapeutics trades under FULC ticker.
When did Fulcrum Therapeutics go public? Fulcrum Therapeutics went public in 2019.
Who are competitors of Fulcrum Therapeutics? Similar companies to Fulcrum Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Fulcrum Therapeutics? Fulcrum Therapeutics's current market cap is $158M
What is the current revenue of Fulcrum Therapeutics? Fulcrum Therapeutics's last 12-month revenue is $57.0M.
What is the current EV/Revenue multiple of Fulcrum Therapeutics? Current revenue multiple of Fulcrum Therapeutics is -1.3x.
What is the current revenue growth of Fulcrum Therapeutics? Fulcrum Therapeutics revenue growth between 2023 and 2024 was 2752%.
Is Fulcrum Therapeutics profitable? Yes, Fulcrum Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.